Treatment of Chronic Posterior Laryngitis With Esomeprazole

TLDR

The study aimed to determine whether esomeprazole 40 mg twice daily improves symptoms and laryngoscopic findings in patients with chronic posterior laryngitis suspected of reflux. A prospective, multicenter, randomized, parallel‑group trial enrolled 145 patients with CPL symptoms and laryngoscopic reflux signs, randomizing them to esomeprazole or placebo for 16 weeks and measuring symptom diaries and CPLI scores. Esomeprazole did not reduce CPL symptoms or CPLI scores compared with placebo, with no significant differences in primary or secondary outcomes, indicating no therapeutic benefit.

Abstract

Abstract Objective: To evaluate the efficacy of acid‐suppressive therapy with the proton pump inhibitor esomeprazole on the signs and symptoms of chronic posterior laryngitis (CPL) in patients with suspected reflux laryngitis. Study Design: Prospective, multicenter, randomized, parallel‐group trial that compared twice‐daily esomeprazole 40 mg with placebo for 16 weeks. Methods: Eligible patients had a history of one or more CPL symptoms (throat clearing, cough, globus, sore throat, or hoarseness) and laryngoscopic signs indicating reflux laryngitis based on CPL index (CPLI) scores measured during a screening laryngoscopy. Patients were randomized to treatment if their 7‐day screening diary‐card recordings showed a cumulative primary symptom score of 9 or higher and they had 3 or more days with moderately severe symptoms based on a 7‐point scale. Efficacy was assessed by changes in symptoms as recorded by patients and investigators and by changes in CPLI scores based on laryngoscopic examinations. Results: The patients' primary CPL symptom at final visit (primary efficacy end point) was resolved in 14.7% (14/95) and 16.0% (8/50) of patients in the esomeprazole and placebo groups, respectively ( P = .799). Esomeprazole and placebo were not significantly different for change from baseline to the final visit in mean total CPLI (–1.66 ± 2.13 vs. –2.0 ± 2.55, respectively; P = .446) or any other secondary efficacy end points based on patient diary card or investigator assessments. Conclusion: This study provides no evidence of a therapeutic benefit of treatment with esomeprazole 40 mg twice daily for 16 weeks compared with placebo for signs and symptoms associated with CPL.